Efficacy of N-carbamoyl-L-glutamic acid for the treatment of inherited metabolic disorders

References

• Brusilow SW, Horwich AL Urea cycle enzymes. The online metabolic and molecuar bases of inherited disease.[ cited 2014 Jan] Available from: http://www.ommbid.com
   Google Scholar
• Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia. Adv Drug Deliv Rev. 2015;90:55–68.
   PubMed Web of Science ®Google Scholar
• Oishi K, Diaz GA. Glycerol phenylbutyrate for the chronic management of urea cycle disorders. Expert Rev Endocrinol Metab. 2014;9(5):427–434.
   PubMedGoogle Scholar
• Haberle J. Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. Ther Clin Risk Manag. 2011;7:327–332.
   PubMedGoogle Scholar
• Bachmann C, Colombo JP, Jaggi K. N-acetylglutamate synthetase (NAGS) deficiency: diagnosis, clinical observations and treatment. Adv Exp Med Biol. 1982;153:39–45.
   PubMed Web of Science ®Google Scholar
• de Cima S, Polo LM, Diez-Fernandez C, et al. Structure of human carbamoyl phosphate synthetase: deciphering the on/off switch of human ureagenesis. Sci Rep. 2015;5:16950.
   PubMed Web of Science ®Google Scholar
• Daniotti M, La Marca G, Fiorini P, et al. New developments in the treatment of hyperammonemia: emerging use of carglumic acid. Int J Gen Med. 2011;4:21–28.
   PubMedGoogle Scholar
• Ah Mew N, Payan I, Daikhin Y, et al. Effects of a single dose of N-carbamylglutamate on the rate of ureagenesis. Mol Genet Metab. 2009;98(4):325–330.
   PubMed Web of Science ®Google Scholar
• Tuchman M, Caldovic L, Daikhin Y, et al. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res. 2008;64(2):213–217.
   PubMed Web of Science ®Google Scholar
• Rubio V, Ramponi G, Grisolia S. Carbamoyl phosphate synthetase I of human liver. Purification, some properties and immunological cross-reactivity with the rat liver enzyme. Biochim Biophys Acta. 1981;659(1):150–160.
   PubMed Web of Science ®Google Scholar
• Fahien LA, Schooler JM, Gehred GA, et al. Studies on the mechanism of action of acetylglutamate as an activator of carbamyl phosphate synthetase. J Biol Chem. 1964;239:1935–1941.
   PubMed Web of Science ®Google Scholar
• Caldovic L, Morizono H, Gracia Panglao M, et al. Cloning and expression of the human N-acetylglutamate synthase gene. Biochem Biophys Res Commun. 2002;299(4):581–586.
   PubMed Web of Science ®Google Scholar
• Bachmann C, Krahenbuhl S, Colombo JP, et al. N-acetylglutamate synthetase deficiency: a disorder of ammonia detoxication. N Engl J Med. 1981;304(9):543.
   PubMed Web of Science ®Google Scholar
• Bachmann C, Brandis M, Weissenbarth-Riedel E, et al. N-acetylglutamate synthetase deficiency, a second patient. J Inherit Metab Dis. 1988;11(2):191–193.
   PubMed Web of Science ®Google Scholar
• Cartagena A, Prasad AN, Rupar CA, et al. Recurrent encephalopathy: NAGS (N-acetylglutamate synthase) deficiency in adults. Can J Neurol Sci. 2013;40(1):3–9.
   PubMed Web of Science ®Google Scholar
• Sancho-Vaello E, Marco-Marin C, Gougeard N, et al. Understanding N-acetyl-L-glutamate synthase deficiency: mutational spectrum, impact of clinical mutations on enzyme functionality, and structural considerations. Hum Mutat. 2016;37(7):679–694.
   PubMed Web of Science ®Google Scholar
• Ah Mew N, Caldovic L. N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment. Appl Clin Genet. 2011;4:127–135.
   PubMedGoogle Scholar
• Haberle J, Schmidt E, Pauli S, et al. Mutation analysis in patients with N-acetylglutamate synthase deficiency. Hum Mutat. 2003;21(6):593–597.
   PubMed Web of Science ®Google Scholar
• Coude FX, Grimber G, Parvy P, et al. Inhibition of ureagenesis by valproate in rat hepatocytes. Role of N-acetylglutamate and acetyl-CoA. Biochem J. 1983;216(1):233–236.
   PubMed Web of Science ®Google Scholar
• Coude FX, Sweetman L, Nyhan WL. Inhibition by propionyl-coenzyme A of N-acetylglutamate synthetase in rat liver mitochondria. A possible explanation for hyperammonemia in propionic and methylmalonic acidemia. J Clin Invest. 1979;64(6):1544–1551.
   PubMed Web of Science ®Google Scholar
• Williams CA, Tiefenbach S, McReynolds JW. Valproic acid-induced hyperammonemia in mentally retarded adults. Neurology. 1984;34(4):550–553.
   PubMed Web of Science ®Google Scholar
• Grisolia S, Cohen PP. The catalytic role of carbamyl glutamate in citrulline biosynthesis. J Biol Chem. 1952;198(2):561–571.
   PubMed Web of Science ®Google Scholar
• Schooler JM, Fahien LA, Cohen PP. 2-Acetoxyglutarate as an activator of carbamyl phosphate synthetase. J Biol Chem. 1963;238:1909–1910.
   PubMed Web of Science ®Google Scholar
• Grisolia S, Cohen PP. Catalytic role of of glutamate derivatives in citrulline biosynthesis. J Biol Chem. 1953;204(2):753–757.
   PubMed Web of Science ®Google Scholar
• Kim S, Paik WK, Cohen PP. Ammonia intoxication in rats: protection by N-carbamoyl-L-glutamate plus L-arginine. Proc Natl Acad Sci U S A. 1972;69(12):3530–3533.
   PubMed Web of Science ®Google Scholar
• Reglero A, Rivas J, Mendelson J, et al. Deacylation and transacetylation of acetyl glutamate and acetyl ornithine in rat liver. FEBS Lett. 1977;81(1):13–17.
   PubMed Web of Science ®Google Scholar
• Guffon N, Schiff M, Cheillan D, et al. Neonatal hyperammonemia: the N-carbamoyl-L-glutamic acid test. J Pediatr. 2005;147(2):260–262.
   PubMed Web of Science ®Google Scholar
• Schubiger G, Bachmann C, Barben P, et al. N-acetylglutamate synthetase deficiency: diagnosis, management and follow-up of a rare disorder of ammonia detoxication. Eur J Pediatr. 1991;150(5):353–356.
   PubMed Web of Science ®Google Scholar
• Gessler P, Buchal P, Schwenk HU, et al. Favourable long-term outcome after immediate treatment of neonatal hyperammonemia due to N-acetylglutamate synthase deficiency. Eur J Pediatr. 2010;169(2):197–199.
   PubMed Web of Science ®Google Scholar
• Caldovic L, Morizono H, Daikhin Y, et al. Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. J Pediatr. 2004;145(4):552–554.
   PubMed Web of Science ®Google Scholar
• Guffon N, Vianey-Saban C, Bourgeois J, et al. A new neonatal case of N-acetylglutamate synthase deficiency treated by carbamylglutamate. J Inherit Metab Dis. 1995;18(1):61–65.
   PubMed Web of Science ®Google Scholar
• Hinnie J, Colombo JP, Wermuth B, et al. N-Acetylglutamate synthetase deficiency responding to carbamylglutamate. J Inherit Metab Dis. 1997;20(6):839–840.
   PubMed Web of Science ®Google Scholar
• Morris AA, Richmond SW, Oddie SJ, et al. N-acetylglutamate synthetase deficiency: favourable experience with carbamylglutamate. J Inherit Metab Dis. 1998;21(8):867–868.
   PubMed Web of Science ®Google Scholar
• Elpeleg O, Shaag A, Ben-Shalom E, et al. N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. Ann Neurol. 2002;52(6):845–849.
   PubMed Web of Science ®Google Scholar
• Sasinowski FJ. Quantum of effectiveness evidence in FDA’s approval of orphan drugs. Drug Information Journal. 2012;46(2):238–263.
   Google Scholar
• Van Leynseele A, Jansen A, Goyens P, et al. Early treatment of a child with NAGS deficiency using N-carbamyl glutamate results in a normal neurological outcome. Eur J Pediatr. 2014;173(12):1635–1638.
   PubMed Web of Science ®Google Scholar
• Kiykim E, Zubarioglu T. Low dose of carglumic acid for treatment of hyperammonemia due to N-acetylglutamate synthase deficiency. Indian Pediatr. 2014;51(9):755–756.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim YM, Lee BH, et al. Short-term efficacy of N-carbamylglutamate in a patient with N-acetylglutamate synthase deficiency. J Hum Genet. 2015;60(7):395–397.
   PubMed Web of Science ®Google Scholar
• Haberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.
   PubMed Web of Science ®Google Scholar
• Caldovic L, Morizono H, Panglao MG, et al. Late onset N-acetylglutamate synthase deficiency caused by hypomorphic alleles. Hum Mutat. 2005;25(3):293–298.
   PubMed Web of Science ®Google Scholar
• Caldovic L, Morizono H, Tuchman M. Mutations and polymorphisms in the human N-acetylglutamate synthase (NAGS) gene. Hum Mutat. 2007;28(8):754–759.
   PubMed Web of Science ®Google Scholar
• Tuchman M, Lee B, Lichter-Konecki U, et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab. 2008;94(4):397–402.
   PubMed Web of Science ®Google Scholar
• Abacan M, Boneh A. Use of carglumic acid in the treatment of hyperammonaemia during metabolic decompensation of patients with propionic acidaemia. Mol Genet Metab. 2013);109(4):397–401.
   PubMed Web of Science ®Google Scholar
• Jones S, Reed CA, Vijay S, et al. N-carbamylglutamate for neonatal hyperammonaemia in propionic acidaemia. J Inherit Metab Dis. 2008;31(Suppl 2):S219–S222.
   PubMed Web of Science ®Google Scholar
• Levesque S, Lambert M, Karalis A, et al. Short-term outcome of propionic aciduria treated at presentation with N-carbamylglutamate: a retrospective review of four patients. JIMD Rep. 2012;2:97–102.
   PubMedGoogle Scholar
• Baumgartner MR, Horster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130.
   PubMed Web of Science ®Google Scholar
• Filippi L, Gozzini E, Fiorini P, et al. N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria. Neonatology. 2010;97(3):286–290.
   PubMed Web of Science ®Google Scholar
• Gebhardt B, Dittrich S, Parbel S, et al. N-carbamylglutamate protects patients with decompensated propionic aciduria from hyperammonaemia. J Inherit Metab Dis. 2005;28(2):241–244.
   PubMed Web of Science ®Google Scholar
• Gebhardt B, Vlaho S, Fischer D, et al. N-carbamylglutamate enhances ammonia detoxification in a patient with decompensated methylmalonic aciduria. Mol Genet Metab. 2003;79(4):303–304.
   PubMed Web of Science ®Google Scholar
• Levrat V, Forest I, Fouilhoux A, et al. Carglumic acid: an additional therapy in the treatment of organic acidurias with hyperammonemia? Orphanet J Rare Dis. 2008;3:2.
   PubMed Web of Science ®Google Scholar
• Schwahn BC, Pieterse L, Bisset WM, et al. Biochemical efficacy of N-carbamylglutamate in neonatal severe hyperammonaemia due to propionic acidaemia. Eur J Pediatr. 2010;169(1):133–134.
   PubMed Web of Science ®Google Scholar
• Kasapkara CS, Ezgu FS, Okur I, et al. N-carbamylglutamate treatment for acute neonatal hyperammonemia in isovaleric acidemia. Eur J Pediatr. 2011;170(6):799–801.
   PubMed Web of Science ®Google Scholar
• Yap S, Leong HY, Abdul Aziz F, et al. N-Carbamylglutamate is an effective treatment for acute neonatal hyperammonaemia in a patient with methylmalonic aciduria. Neonatology. 2016;109(4):303–307.
   PubMed Web of Science ®Google Scholar
• Ah Mew N, McCarter R, Daikhin Y, et al. N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics. 2010;126(1):e208–e214.
   PubMed Web of Science ®Google Scholar
• Valayannopoulos V, Baruteau J, Delgado MB, et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study. Orphanet J Rare Dis. 2016;11(1):32.
   PubMed Web of Science ®Google Scholar
• Tummolo A, Favia V, Bellantuono R, et al. Successful early management of a female patient with a metabolic stroke due to ornithine transcarbamylase deficiency. Pediatr Emerg Care. 2013;29(5):656–658.
   PubMed Web of Science ®Google Scholar
• Diez-Fernandez C, Martinez AI, Pekkala S, et al. Molecular characterization of carbamoyl-phosphate synthetase (CPS1) deficiency using human recombinant CPS1 as a key tool. Hum Mutat. 2013;34(8):1149–1159.
   PubMed Web of Science ®Google Scholar
• Diez-Fernandez C, Gallego J, Haberle J, et al. The study of carbamoyl phosphate synthetase 1 deficiency sheds light on the mechanism for switching on/off the urea cycle. J Genet Genomics. 2015;42(5):249–260.
   PubMed Web of Science ®Google Scholar
• Ah Mew N, McCarter R, Daikhin Y, et al. Augmenting ureagenesis in patients with partial carbamyl phosphate synthetase 1 deficiency with N-carbamyl-L-glutamate. J Pediatr. 2014;165(2):e401–e403.
   PubMed Web of Science ®Google Scholar
• Strauss KA, Puffenberger EG, Morton DH. Maple Syrup Urine Disease. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997–2013. 2006 [updated 2013 May 9; cited 2016 May 29]. Available from: http://www.genetests.org. according to NCBI citation guideline.
   Google Scholar
• Kalkan Ucar S, Coker M, Habif S, et al. The first use of N-carbamylglutamate in a patient with decompensated maple syrup urine disease. Metab Brain Dis. 2009;24(3):409–414.
   PubMed Web of Science ®Google Scholar
• van Karnebeek CD, Sly WS, Ross CJ, et al. Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood. Am J Hum Genet. 2014;94(3):453–461.
   PubMed Web of Science ®Google Scholar
• Aires CC, van Cruchten A, Ijlst L, et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol. 2011;55(2):426–434.
   PubMed Web of Science ®Google Scholar
• Kasapkara CS, Kangin M, Tas FF, et al. Unusual cause of hyperammonemia in two cases with short-term and long-term valproate therapy successfully treated by single dose carglumic acid. J Pediatr Neurosci. 2013;8(3):250–252.
   PubMedGoogle Scholar
• Nott L, Price TJ, Pittman K, et al. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma. 2007;48(9):1702–1711.
   PubMed Web of Science ®Google Scholar
• Chan JS, Harding CO, Blanke CD. Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency. South Med J. 2008;101(5):543–545.
   PubMed Web of Science ®Google Scholar
• Jeffers LJ, Dubow RA, Zieve L, et al. Hepatic encephalopathy and orotic aciduria associated with hepatocellular carcinoma in a noncirrhotic liver. Hepatology. 1988;8(1):78–81.
   PubMed Web of Science ®Google Scholar
• Lazier J, Lupichuk SM, Sosova I, et al. Hyperammonemic encephalopathy in an adenocarcinoma patient managed with carglumic acid. Curr Oncol. 2014;21(5):e736–e739.
   PubMed Web of Science ®Google Scholar
• Winter SS, Rose E, Katz R. Hyperammonemia after chemotherapy in an adolescent with hepatocellular carcinoma. J Pediatr Gastroenterol Nutr. 1997;25(5):537–540.
   PubMed Web of Science ®Google Scholar
• Chen CT, Chen YC, Yamaguchi H, et al. Carglumic acid promotes apoptosis and suppresses cancer cell proliferation in vitro and in vivo. Am J Cancer Res. 2015;5(12):3560–3569.
   PubMed Web of Science ®Google Scholar
• Wu X, Wan D, Xie C, et al. Acute and sub-acute oral toxicological evaluations and mutagenicity of N-carbamylglutamate (NCG). Regul Toxicol Pharmacol. 2015;73(1):296–302.
   PubMed Web of Science ®Google Scholar
• Soyucen E, Demirci E, Aydin A. Outpatient treatment of propionic acidemia-associated hyperammonemia with N-carbamoyl-L-glutamate in an infant. Clin Ther. 2010;32(4):710–713.
   PubMed Web of Science ®Google Scholar
• Kim WH, Park H, Yun C, et al. Mixture of N-carbamoyl-L-glutamate plus L-arginine can protect rats with liver cirrhosis from acute ammonia intoxication. J Hepatol. 2001;35(6):719–725.
   PubMed Web of Science ®Google Scholar
• Caldovic L, Ah Mew N, Shi D, et al. N-acetylglutamate synthase: structure, function and defects. Mol Genet Metab. 2010;100(Suppl 1):S13–S19.
   PubMed Web of Science ®Google Scholar